Stiripentol's Mechanism in Resistant Seizures
Stiripentol treats Dravet syndrome-related resistant seizures primarily as a positive allosteric modulator of GABAA receptors. It enhances GABAergic inhibition by increasing chloride channel opening at low GABA concentrations, boosting tonic inhibition without direct receptor agonism. It also inhibits several cytochrome P450 enzymes (CYP2C19, CYP3A4, CYP2D6), slowing metabolism of clobazam and other antiseizure drugs to raise their levels.[1]
Fenfluramine's Mechanism in Resistant Seizures
Fenfluramine targets Dravet syndrome seizures through multiple pathways: it promotes serotonin release via inhibition of the serotonin transporter (SERT), activates sigma-1 receptors to modulate neuronal excitability, and enhances tonic GABAA receptor-mediated inhibition indirectly. Its active metabolite, norfenfluramine, contributes strongly to sigma-1 agonism, which stabilizes neuronal membranes during hyperexcitability.[1][2]
Key Differences in Their Mechanisms
Stiripentol acts directly on GABAA receptors for enhanced GABAergic tone and relies on CYP inhibition for pharmacokinetic synergy with other drugs, with no major serotonergic or sigma-1 effects. Fenfluramine, by contrast, drives serotonin release and sigma-1 activation as primary drivers, indirectly supporting GABA inhibition. This makes stiripentol more purely GABA-focused, while fenfluramine's multi-target profile (serotonergic + sigma-1) addresses broader network hyperexcitability in Dravet syndrome.[1][3]
| Aspect | Stiripentol | Fenfluramine |
|--------|-------------|--------------|
| Primary Target | GABAA allosteric modulation | Serotonin release (SERT inhibition) + sigma-1 agonism |
| GABA Effect | Direct enhancement of tonic inhibition | Indirect via network modulation |
| Metabolic Role | Strong CYP inhibitor | Minimal; metabolized to active norfenfluramine |
| Non-GABA Pathways | None significant | Serotonergic and sigma-1 dominant |
Why These Differences Matter for Resistant Seizures
Stiripentol's GABA specificity suits cases with prominent inhibitory deficits, often combined with clobazam for amplified effect. Fenfluramine's serotonin/sigma-1 actions target Dravet's sodium channel mutations (SCN1A) more broadly, reducing seizure frequency even in stiripentol non-responders. Trials show fenfluramine adds ~50% seizure reduction atop stiripentol in some patients.[3][4]
Clinical Overlaps and Combination Use
Both are FDA-approved for Dravet syndrome seizures ≥2 years old, often used together or with cannabidiol/stiripentol. No head-to-head trials exist, but real-world data indicate complementary mechanisms: stiripentol for baseline GABA boost, fenfluramine for breakthrough control.[4]
Potential Side Effects Tied to Mechanisms
Stiripentol's CYP inhibition raises risks of sedation or elevated clobazam levels. Fenfluramine's serotonergic action carries cardiac valve risks (monitored via echocardiograms) and weight loss, linked to sigma-1 effects.[2][4]
[1]: DrugPatentWatch.com - Stiripentol Patents
[2]: DrugPatentWatch.com - Fenfluramine Patents
[3]: French JA et al. Lancet Neurol 2019;18:1080-1091 (fenfluramine mechanism review)
[4]: Lagae L et al. Epilepsia 2020;61:2798-2808 (Dravet combo therapy data)